A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
Prolyl hydroxylase (PH) enzymes control the degradation of hypoxia-inducible factor (HIF), a transcription factor known to regulate erythropoiesis, angiogenesis, glucose metabolism, cell proliferation, and apoptosis. HIF-PH inhibitors (HIF-PHIs) correct anemia in patients with renal disease and in a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0255022 |
| _version_ | 1818570543447670784 |
|---|---|
| author | Pierre E Signore Guangjie Guo Zhihua Wei Weihua Zhang Al Lin Ughetta Del Balzo |
| author_facet | Pierre E Signore Guangjie Guo Zhihua Wei Weihua Zhang Al Lin Ughetta Del Balzo |
| author_sort | Pierre E Signore |
| collection | DOAJ |
| description | Prolyl hydroxylase (PH) enzymes control the degradation of hypoxia-inducible factor (HIF), a transcription factor known to regulate erythropoiesis, angiogenesis, glucose metabolism, cell proliferation, and apoptosis. HIF-PH inhibitors (HIF-PHIs) correct anemia in patients with renal disease and in animal models of anemia and kidney disease. However, the effects of HIF-PHIs on comorbidities associated with kidney disease remain largely unknown. We evaluated the effects of the HIF-PHI FG-2216 in obese ZSF1 (Ob-ZSF1) rats, an established model of kidney failure with metabolic syndrome. Following unilateral nephrectomy (Nx) at 8 weeks of age, rats were treated with 40 mg/kg FG-2216 or vehicle by oral gavage three times per week for up to 18 weeks. FG-2216 corrected blood hemoglobin levels and improved kidney function and histopathology in Nx-Ob-ZSF1 rats by increasing the glomerular filtration rate, decreasing proteinuria, and reducing peritubular fibrosis, tubular damage, glomerulosclerosis and mesangial expansion. FG-2216 increased renal glucose excretion and decreased body weight, fat pad weight, and serum cholesterol in Nx-Ob-ZSF1 rats. Additionally, FG-2216 corrected hypertension, improved diastolic and systolic heart function, and reduced cardiac hypertrophy and fibrosis. In conclusion, the HIF-PHI FG-2216 improved renal and cardiovascular outcomes, and reduced obesity in a rat model of kidney disease with metabolic syndrome. Thus, in addition to correcting anemia, HIF-PHIs may provide renal and cardiac protection to patients suffering from kidney disease with metabolic syndrome. |
| first_indexed | 2024-12-14T13:43:08Z |
| format | Article |
| id | doaj.art-29b1b5bc4f374084a6a0d5b79eeb70af |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T13:43:08Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-29b1b5bc4f374084a6a0d5b79eeb70af2022-12-21T22:59:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01168e025502210.1371/journal.pone.0255022A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.Pierre E SignoreGuangjie GuoZhihua WeiWeihua ZhangAl LinUghetta Del BalzoProlyl hydroxylase (PH) enzymes control the degradation of hypoxia-inducible factor (HIF), a transcription factor known to regulate erythropoiesis, angiogenesis, glucose metabolism, cell proliferation, and apoptosis. HIF-PH inhibitors (HIF-PHIs) correct anemia in patients with renal disease and in animal models of anemia and kidney disease. However, the effects of HIF-PHIs on comorbidities associated with kidney disease remain largely unknown. We evaluated the effects of the HIF-PHI FG-2216 in obese ZSF1 (Ob-ZSF1) rats, an established model of kidney failure with metabolic syndrome. Following unilateral nephrectomy (Nx) at 8 weeks of age, rats were treated with 40 mg/kg FG-2216 or vehicle by oral gavage three times per week for up to 18 weeks. FG-2216 corrected blood hemoglobin levels and improved kidney function and histopathology in Nx-Ob-ZSF1 rats by increasing the glomerular filtration rate, decreasing proteinuria, and reducing peritubular fibrosis, tubular damage, glomerulosclerosis and mesangial expansion. FG-2216 increased renal glucose excretion and decreased body weight, fat pad weight, and serum cholesterol in Nx-Ob-ZSF1 rats. Additionally, FG-2216 corrected hypertension, improved diastolic and systolic heart function, and reduced cardiac hypertrophy and fibrosis. In conclusion, the HIF-PHI FG-2216 improved renal and cardiovascular outcomes, and reduced obesity in a rat model of kidney disease with metabolic syndrome. Thus, in addition to correcting anemia, HIF-PHIs may provide renal and cardiac protection to patients suffering from kidney disease with metabolic syndrome.https://doi.org/10.1371/journal.pone.0255022 |
| spellingShingle | Pierre E Signore Guangjie Guo Zhihua Wei Weihua Zhang Al Lin Ughetta Del Balzo A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. PLoS ONE |
| title | A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. |
| title_full | A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. |
| title_fullStr | A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. |
| title_full_unstemmed | A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. |
| title_short | A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. |
| title_sort | small molecule inhibitor of hypoxia inducible factor prolyl hydroxylase improves obesity nephropathy and cardiomyopathy in obese zsf1 rats |
| url | https://doi.org/10.1371/journal.pone.0255022 |
| work_keys_str_mv | AT pierreesignore asmallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT guangjieguo asmallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT zhihuawei asmallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT weihuazhang asmallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT allin asmallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT ughettadelbalzo asmallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT pierreesignore smallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT guangjieguo smallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT zhihuawei smallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT weihuazhang smallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT allin smallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats AT ughettadelbalzo smallmoleculeinhibitorofhypoxiainduciblefactorprolylhydroxylaseimprovesobesitynephropathyandcardiomyopathyinobesezsf1rats |